EMA Authorised: Mircera (Methoxy polyethylene glycol-epoetin beta) — Roche Registration GmbH

View source ↗

Summary

Mircera (methoxy polyethylene glycol-epoetin beta) has been authorized by the EMA for the treatment of anemia, including in chronic kidney disease. The marketin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Status: Authorised. Therapeutic area: Anemia;Kidney Failure, Chronic. MAH: Roche Registration GmbH. Decision date: 30/01/2025